Zusammenfassung der Höchst- und Tiefststände sowie der Veränderungen der Aktienkurse für Waters
Historische Aktienkurse
Aktueller Aktienkurs	US$376.89
52-Wochen-Hoch	US$414.15
52-Wochen-Tief	US$275.05
Beta	1.2
1 Monat Veränderung	11.30%
3 Monate Veränderung	30.34%
1 Jahr Veränderung	6.19%
3 Jahre Veränderung	43.88%
5 Jahre Veränderung	7.32%
Veränderung seit IPO	9,867.34%

Aktuelle Nachrichten und Updates

Narrativ-Update • Jun 18

WAT: Battery Safety And Omics Platforms Will Drive Future Stock Upside

Analysts maintained their $460.00 price target on Waters, citing relatively steady assumptions around revenue growth, profit margin, and future P/E, which offset the slightly higher discount rate in their valuation work. What’s in the News for Waters Waters launched the TA Instruments Coin Cell Differential Scanning Calorimeter, combining thermal, evolved gas, and electrochemical analysis in a single experiment to support earlier insights into battery thermal runaway and reduce cell teardown time by over 90% (source: company announcement, 9 June 2026).

Analyseartikel • Jun 16

Waters (WAT) Stock Could Be 8.3% Undervalued After Product Launches And FDA Clearance

Waters (WAT) is in focus after launching its BioResolve Peptide and GTxResolve Lipid columns and securing FDA 510(k) clearance for the BD BACTEC FXI Culture System, developments that expand its biopharma and diagnostics footprint. See our latest analysis for Waters. Despite the product launches and diagnostics clearance, Waters’ share price shows mixed momentum, with a 30 day share price return of 9.51% and a 90 day share price return of 22.20%, while the 1 year total shareholder return sits...

Recent updates

Narrativ-Update • Jun 18

WAT: Battery Safety And Omics Platforms Will Drive Future Stock Upside

Analyseartikel • Jun 16

Waters (WAT) Stock Could Be 8.3% Undervalued After Product Launches And FDA Clearance

Narrativ-Update • Jun 03

WAT: New Omics Platforms And Buybacks Will Support Future Upside

Analysts have trimmed their price target for Waters to $460, reflecting slightly higher assumed discount rates, modestly adjusted long term revenue growth and profit margin expectations, and a lower future P/E multiple in their updated models. What's in the News Waters launched the Cyclic IMS P20 Mass Spectrometer, a structural and spatial omics platform using multipass Cyclic Ion Mobility Spectrometry and advanced fragmentation and imaging techniques, aimed at earlier detection of disease signals and more detailed molecular visualization.

Analyseartikel • May 19

Earnings Troubles May Signal Larger Issues for Waters (NYSE:WAT) Shareholders

Investors weren't pleased with the recent soft earnings report from Waters Corporation ( NYSE:WAT ). We did some...

Narrativ-Update • May 18

WAT: New Product Launches And Completed Buybacks Will Support Future Upside

Analysts now set a slightly higher price target for Waters at about $478, up from about $470, reflecting updated views on its fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Waters issued earnings guidance for the second quarter of 2026, with expected total revenue between US$1.616b and US$1.631b, and for full year 2026, with expected total revenue between US$6.405b and US$6.455b on a reported basis (Corporate guidance).

Narrativ-Update • May 01

WAT: New Instrument Launches And Reorganized Divisions Will Support Future Upside

Analysts have trimmed their price target on Waters from $480 to $470, citing updated assumptions for significantly higher revenue growth at 37.91%, a profit margin of 17.88%, a prospective P/E of 47.70 and a discount rate of 7.89%. What's in the News Waters plans to globally launch the omniDAWN Multi Angle Light Scattering Photometer in summer 2026, targeting UHPLC and UPLC workflows for absolute molar mass and size measurements across complex analytes such as protein aggregates, viral vectors, lipid nanoparticles, and advanced materials (Key Developments).

Narrativ-Update • Apr 17

WAT: Reorganization And Product Pipeline Will Likely Keep Upside In Check

Analysts have kept their price target for Waters steady at $330.00, citing updated assumptions for slightly higher revenue growth, a wider profit margin, and a higher future P/E multiple as the key drivers behind the unchanged fair value view. What's in the News Launched the Waters omniDAWN Multi-Angle Light Scattering Photometer for UHPLC and UPLC workflows, targeting absolute molar mass and size measurements for complex analytes such as protein aggregates, viral vectors, lipid nanoparticles, and advanced materials.

Narrativ-Update • Apr 03

WAT: New Four Division Model And Materials Focus Will Support Higher Profitability

Analysts have reduced their price target on Waters by about $5 to $393, reflecting small adjustments to fair value assumptions, discount rate, revenue growth, profit margin and future P/E inputs. What's in the News Waters launched the TA Instruments ARES-G3 Rheometer, a next generation system that captures up to 25,000 data points per second, aims to shorten standard test times by up to 80%, and is available for order as part of the materials characterization portfolio (Key Developments).

Narrativ-Update • Mar 20

WAT: New Four Division Model Will Support Higher Long Term Profitability

Analysts have kept their price target for Waters steady at $398.05. This reflects updated views on a slightly lower discount rate, modestly adjusted revenue growth expectations, a higher projected profit margin, and a reduced future P/E assumption.

Seeking Alpha • Mar 10

Waters: Doing Well, Acquired Activities Not So Much

Summary Waters' shares have retreated to the $300 level, presenting a renewed buying opportunity after initial post-acquisition gains evaporated. The $17.5B acquisition of Becton, Dickinson's Biosciences & Diagnostics Solutions expands Waters scale, though acquired business growth appears soft versus initial expectations. Waters guides 2026 sales to $6.405–$6.455B and adjusted EPS to $14.30–$14.50, reflecting early synergies and manageable leverage. At 21x earnings, Waters is not historically cheap, but synergy potential and deleveraging support a more upbeat outlook at current levels. Read the full article on Seeking Alpha

Narrativ-Update • Mar 05

WAT: New Four Division Structure Will Support Higher Long Term Earnings

Analysts have nudged their price target for Waters higher to $398.05 from $394.68, reflecting updated assumptions that combine a higher revenue growth outlook, a lower projected profit margin, and a richer future P/E multiple. What's in the News Waters has closed a transaction and reorganized into four divisions, aligning its operations with high volume testing in regulated applications and adjacent markets such as therapeutics, food, environmental testing, and specialty diagnostics (Key Developments).

Narrativ-Update • Feb 19

WAT: Reorganization And Margin Pressure Will Likely Cap Upside For Now

Analysts now mark their price target for Waters at $330, down from $349, citing updated assumptions around revenue growth, profit margins, discount rate, and future P/E that change their overall valuation framework. What's in the News Waters closed a transaction and reorganized into four divisions focused on high-volume testing and adjacent markets, now grouped as Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials Sciences (company announcement).

Narrativ-Update • Feb 05

WAT: New Detector Launch And Higher Margins Will Likely Disappoint Optimists

Analysts have modestly lifted their price target for Waters to about $349, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E as the key drivers of this small adjustment from roughly $348.15. What's in the News Waters has scheduled a special or extraordinary shareholders meeting for January 27, 2026, to be held online via proxydocs.com/wat in the United States (Key Developments).

Narrativ-Update • Jan 22

WAT: New Detector Launch And Stable Margins Will Support Future Upside

Analysts kept their price target for Waters steady at US$480.00, with only very small tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions, reflecting fine-tuning rather than a major shift in their view. What's in the News Waters scheduled a special or extraordinary shareholders meeting for January 27, 2026, to be held via proxydocs.com/wat in the United States (company event filing).

Narrativ-Update • Jan 08

WAT: Higher Margins And New Product Launch Will Support Future Upside

Analysts have lifted their price target on Waters to US$480 from about US$424, citing updated assumptions for slightly higher revenue growth, profit margins near 26%, and a modestly higher future P/E multiple. What's in the News Waters scheduled a special or extraordinary shareholders meeting for January 27, 2026, to be held online via proxydocs.com/wat (Special/Extraordinary Shareholders Meeting).

Analyseartikel • Jan 04

Estimating The Intrinsic Value Of Waters Corporation (NYSE:WAT)

Key Insights Waters' estimated fair value is US$362 based on 2 Stage Free Cash Flow to Equity Waters' US$382 share...

Narrativ-Update • Dec 25

WAT: Future Product Expansion Will Likely Fail To Justify Current Optimism

Analysts have raised their price target on Waters from 300.00 dollars to 348.15 dollars, citing slightly stronger expectations for revenue growth, profit margins, and future valuation multiples. What's in the News Launched a new Charged Aerosol Detector optimized for Empower Software, expanding capabilities for measuring analytes with little or no UV absorption across pharmaceuticals, food, and environmental testing, with shipments expected by April 2026 (company product announcement).

Narrativ-Update • Dec 10

WAT: Future Margin Gains And New Instruments Will Support Measured Earnings Outlook

Narrative Update on Waters Analysts have modestly raised their price target on Waters by approximately $6 per share, reflecting slightly lower discount rate assumptions, a small improvement in projected profit margins, and a marginally higher future P/E multiple that together support a higher fair value estimate. What's in the News Launched a new Charged Aerosol Detector, purpose built for Empower chromatography software, expanding Waters portfolio of LC detectors and strengthening its position in compliant, high sensitivity analysis for low UV analytes, with shipments expected by April 2026 (Key Developments) Unveiled the Xevo Charge Detection Mass Spectrometer to enable high resolution characterization of very large biomolecules that are central to next generation therapeutics, leveraging technology acquired from Indiana University and Megadalton Solutions (Key Developments) Raised full year 2025 guidance and now expects constant currency sales growth of 6.7% to 7.3% and GAAP EPS of 11.10 to 11.20 dollars per diluted share (Key Developments) Issued new guidance for the fourth quarter of 2025, targeting constant currency sales growth of 5.0% to 7.0% and GAAP EPS of 4.10 to 4.20 dollars per diluted share (Key Developments) Completed its multi year share repurchase program announced in January 2019, buying back more than 15.1 million shares for approximately 3.8 billion dollars in total consideration (Key Developments) Valuation Changes The fair value estimate has risen slightly to approximately $395 per share from about $389 per share, reflecting modest valuation upside.

Narrativ-Update • Nov 26

WAT: Future Margins And Expanded Guidance Will Offset Slower Revenue Trends

Narrative Update on Waters: Analyst Price Target Revision Analysts have raised their price target for Waters, increasing the fair value estimate by $5.71 to $388.58. This revision is attributed to improved profit margin projections, even as revenue growth expectations have slowed.

Narrativ-Update • Nov 07

WAT: Revenue Momentum And Expanded Guidance Will Balance Margin Risks Ahead

Analysts have raised their price target for Waters from $355.74 to $382.87. They cite significantly higher expected revenue growth, which outweighs a slight decrease in projected profit margins.

Narrativ-Update • Oct 23

Emerging Technologies And Share Repurchases Will Support Long-Term Market Opportunities

Narrative Update on Waters Analysts have slightly raised their price target for Waters from $351.07 to $355.74. This change is attributed to modest improvements in projected revenue growth and fair value estimates.

Narrativ-Update • Oct 09

Pharmaceutical R&D And Merger Will Unlock Future Market Potential

Analysts have raised their price target for Waters to $351.07 from $347.14, citing expectations of stronger profit margins and steady revenue growth ahead. What's in the News Waters Corporation raised its earnings guidance for the full year 2025 and projects constant currency sales growth between 5.5% and 7.5%.

Analyseartikel • Sep 19

Risks To Shareholder Returns Are Elevated At These Prices For Waters Corporation (NYSE:WAT)

Waters Corporation's ( NYSE:WAT ) price-to-earnings (or "P/E") ratio of 27.6x might make it look like a sell right now...

Narrativ-Update • Sep 04

Pharmaceutical R&D And Merger Will Unlock Future Market Potential

With no changes in revenue growth expectations or discount rate, Waters’ fair value estimate remains stable, as reflected in the unchanged consensus analyst price target of $350.24. What's in the News Completed buyback program with 15,195,844 shares repurchased for $3,790.62 million, representing 22.96% of shares.

Analyseartikel • Jul 24

Are Investors Undervaluing Waters Corporation (NYSE:WAT) By 36%?

Key Insights Using the 2 Stage Free Cash Flow to Equity, Waters fair value estimate is US$465 Waters is estimated to be...

Analyseartikel • Jul 06

These 4 Measures Indicate That Waters (NYSE:WAT) Is Using Debt Reasonably Well

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Seeking Alpha • Feb 21

Waters Corporation: Instrument Replacement Cycle Momentum, But Valuation Is A Concern

Summary Waters Corp reported better-than-expected Q4'24 and FY'24 results, driven by strong performance in academia, government, and pharma segments, despite FX headwinds impacting gross margins. The company anticipates continued growth in 2025, with projected revenue growth between 4.5% and 7%, supported by emerging markets like India and high-growth areas like GLP-1 and PFAS testing. Risks include elevated valuations and limited opportunities for cash deployment, making buybacks less attractive; current valuation appears challenging compared to historical averages and peers. I rate Waters Corp as a 'hold' due to solid recovery and growth potential, but caution investors to consider the premium pricing relative to value. Read the full article on Seeking Alpha

Seeking Alpha • Jan 29

Weighing In On Waters Corporation: Facing A Valuation Headwind

Summary Today, we take a more in-depth look at Waters Corporation, which provides analytical workflow solutions, primarily to the Pharma and Industrial industries. WAT stock has surged 35% since July lows, but analysts are growing increasingly cautious due to valuation concerns, with mixed ratings and tepid price targets. From a historical perspective, the equity now trades at the very top of its historical P/S and P/E ratios. Can WAT shares rally with this valuation headwind? An analysis of Waters Corporation follows in the paragraphs below. Read the full article on Seeking Alpha

Seeking Alpha • Nov 13

Waters Corp: Short Reinvestment Runway Diminishes High Multiples

Summary Despite a 13% stock appreciation, I maintain a neutral stance on Waters Corporation due to factors outlined in this report. Q3 FY'24 results show mixed regional performance, with China sales still a drag on performance. Opportunities to redeploy surplus funds at an advantage appear limited, reducing compounding ability. Read the full article on Seeking Alpha

Seeking Alpha • Aug 15

Waters Corp.: Embedded Expectations High Under Present Conditions

Summary Waters continues to present with high-quality business characteristics, including high returns on capital employed and loads of freely available cash. Embedded expectations remain exquisitely high, calling for outsized performance in a time when business returns may be contracting. Present multiples demand high compounding rate of operating capital, which reduces the margin of safety. Reiterate hold. Read the full article on Seeking Alpha

Seeking Alpha • May 24

Waters Corporation: Still Struggling A Bit

Summary Waters Corporation reported mediocre first quarter results with the top and bottom line declining. According to fiscal 2024 guidance, the company is still not expecting growth but due to the wide economic moat, we should be optimistic for long-term growth. At this point, Waters Corporation is fairly valued at best and still not a great investment. Read the full article on Seeking Alpha

Aktionärsrenditen

	WAT	US Life Sciences	US Markt
7D	6.0%	9.0%	-2.7%
1Y	6.2%	15.2%	18.6%

Rendite im Vergleich zur Industrie: WAT unter dem Niveau der Branche US Life Sciences , die im vergangenen Jahr eine Rendite von 15.2% erzielte.

Rendite vs. Markt: WAT hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 18.6 erzielte.

Preisvolatilität

Is WAT's price volatile compared to industry and market?
WAT volatility
WAT Average Weekly Movement	6.4%
Life Sciences Industry Average Movement	8.7%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.9%
10% least volatile stocks in US Market	3.1%

Stabiler Aktienkurs: WAT hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.

Volatilität im Zeitverlauf: WATDie wöchentliche Volatilität (6%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1958	7,900	Udit Batra	www.waters.com

Die Waters Corporation bietet analytische Workflow-Lösungen in Asien, Nord- und Südamerika und Europa an. Das Unternehmen ist in zwei Segmenten tätig, Waters und TA. Das Unternehmen entwickelt, fertigt, verkauft und wartet Systeme für die Flüssigchromatographie und die Massenspektrometrie (MS) und unterstützt Produkte, einschließlich Chromatographiesäulen und andere Verbrauchsmaterialien.

Waters Corporation's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Waters im Vergleich zum Marktanteil des Unternehmens?
WAT grundlegende Statistiken
Marktanteil	US$36.25b
Gewinn(TTM)	US$449.63m
Umsatz(TTM)	US$3.77b

82.3x

Kurs-Gewinn-Verhältnis

9.8x

Kurs-Umsatz-Verhältnis

Ist WAT zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
WAT Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$3.77b
Kosten der Einnahmen	US$1.69b
Bruttogewinn	US$2.08b
Sonstige Ausgaben	US$1.63b
Gewinn	US$449.63m

Zuletzt gemeldete Gewinne

Apr 04, 2026

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	4.58
Bruttomarge	55.15%
Nettogewinnspanne	11.93%
Schulden/Eigenkapital-Verhältnis	34.3%

Wie hat sich WAT auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2026/06/25 11:17
Aktienkurs zum Tagesende	2026/06/25 00:00
Gewinne	2026/04/04
Jährliche Einnahmen	2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Waters Corporation wird von 40 Analysten beobachtet. 21 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Catherine Ramsey Schulte	Baird
Charles Butler	Barclays
Luke Sergott	Barclays

Waters (WAT) Aktienübersicht

Belohnungen

Risikoanalyse

Analyst Price Targets

Emerging Technologies And Share Repurchases Will Support Long-Term Market Opportunities

LC-MS And Biotech Expansion Will Unlock Secular Healthcare Demand

Pharma Cost Pressures Will Erode Value But Foster Adaptation

Top Analyst Narratives

Emerging Technologies And Share Repurchases Will Support Long-Term Market Opportunities

LC-MS And Biotech Expansion Will Unlock Secular Healthcare Demand

Pharma Cost Pressures Will Erode Value But Foster Adaptation

Waters Corporation Wettbewerber

Agilent Technologies

IQVIA Holdings

West Pharmaceutical Services

Illumina

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Waters Announces IMU Biosciences Partnership to Advance AI Immune Profiling Platform

WAT: Battery Safety And Omics Platforms Will Drive Future Stock Upside

Waters (WAT) Stock Could Be 8.3% Undervalued After Product Launches And FDA Clearance

Waters Unveils New Columns and Calorimeter Targeting Faster Biopharma and Battery Analysis

Waters Corporation Launches BioResolve Peptide and GTxResolve Lipid Phenyl-Hexyl+ and C18+ Columns

Waters Corporation Announces FDA 510(k) Clearance Of BD BACTEC FXI Culture System

Recent updates

Waters Announces IMU Biosciences Partnership to Advance AI Immune Profiling Platform

WAT: Battery Safety And Omics Platforms Will Drive Future Stock Upside

Waters (WAT) Stock Could Be 8.3% Undervalued After Product Launches And FDA Clearance

Waters Unveils New Columns and Calorimeter Targeting Faster Biopharma and Battery Analysis

Waters Corporation Launches BioResolve Peptide and GTxResolve Lipid Phenyl-Hexyl+ and C18+ Columns

Waters Corporation Announces FDA 510(k) Clearance Of BD BACTEC FXI Culture System

Consensus EPS estimates fall by 12%

WAT: New Omics Platforms And Buybacks Will Support Future Upside

Waters Corporation Unveils Cyclic Ims P20 Ms

Waters Expands Mass Spectrometry Portfolio With New Systems for Multiomics and Spatial Omics Research

Earnings Troubles May Signal Larger Issues for Waters (NYSE:WAT) Shareholders

WAT: New Product Launches And Completed Buybacks Will Support Future Upside

New minor risk - Profit margin trend

First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind

Waters Corporation Provides Earnings Guidance for the Second Quarter Ending July 4, 2026 and Full Year Ending December 31, 2026

WAT: New Instrument Launches And Reorganized Divisions Will Support Future Upside

WAT: Reorganization And Product Pipeline Will Likely Keep Upside In Check

Waters Corporation Debuts Industry-First Extended-Range MALS Detector for UHPLC/UPLC Powering Rapid Characterization of Large Molecules

Waters Corporation, Annual General Meeting, May 21, 2026

Waters Corporation Announces U.S. Food and Drug Administration Clearance of the Most Comprehensive At-Home Cervical Cancer Screening Tool, the Onclarity HPV Self-Collection Kit and FDA-Approved HPV Assay

WAT: New Four Division Model And Materials Focus Will Support Higher Profitability

WAT: New Four Division Model Will Support Higher Long Term Profitability

Waters Corporation Launches ARES-G3 Rheometer

Waters: Doing Well, Acquired Activities Not So Much

WAT: New Four Division Structure Will Support Higher Long Term Earnings

WAT: Reorganization And Margin Pressure Will Likely Cap Upside For Now

New major risk - Shareholder dilution

Waters Corporation Provides Earnings Guidance for the First Quarter Ending April 4, 2026 and Full Year Ending December 31, 2026

Full year 2025 earnings: EPS misses analyst expectations

Waters Corporation (NYSE:WAT) completed the acquisition of Biosciences and Diagnostics Solutions Business of Becton, Dickinson and Company (NYSE:BDX) in a transaction valued at $18.8 billion.

Waters Corporation Appoints Claire M. Fraser to Its Board of Directors

WAT: New Detector Launch And Higher Margins Will Likely Disappoint Optimists

Waters Corporation to Report Q4, 2025 Results on Feb 09, 2026

WAT: New Detector Launch And Stable Margins Will Support Future Upside

WAT: Higher Margins And New Product Launch Will Support Future Upside

Estimating The Intrinsic Value Of Waters Corporation (NYSE:WAT)

WAT: Future Product Expansion Will Likely Fail To Justify Current Optimism

WAT: Future Margin Gains And New Instruments Will Support Measured Earnings Outlook

WAT: Future Margins And Expanded Guidance Will Offset Slower Revenue Trends

Waters Corporation Boosts Lab Productivity and Sample Throughput with Launch of Its Charged Aerosol Detector Designed for Empower Software

WAT: Revenue Momentum And Expanded Guidance Will Balance Margin Risks Ahead

Price target increased by 7.6% to US$383

Waters Corporation Raises Earnings Guidance for the Fourth Quarter and Full Year Ending December 31, 2025

Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Emerging Technologies And Share Repurchases Will Support Long-Term Market Opportunities

Pharmaceutical R&D And Merger Will Unlock Future Market Potential

Waters Corporation to Report Q3, 2025 Results on Nov 04, 2025

Risks To Shareholder Returns Are Elevated At These Prices For Waters Corporation (NYSE:WAT)

Price target decreased by 7.2% to US$347

Pharmaceutical R&D And Merger Will Unlock Future Market Potential

Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Waters Corporation Raises Earnings Guidance for the Full Year 2025

Are Investors Undervaluing Waters Corporation (NYSE:WAT) By 36%?

Investor sentiment deteriorates as stock falls 17%

Waters Corporation (NYSE:WAT) entered into a definitive agreement to acquire Biosciences and Diagnostics Solutions Business of Becton Dickinson and Company in a transaction valued at $17.5 billion.